Horizons Marijuana Life Sciences Index ETF

With the exception of Aphria, Tilray, Canopy Growth, and Aurora Cannabis were trading at a premium to the peer median EV-to-EBITDA multiple.

Jim Cramer said Altria’s acquisition of a 45% stake in Cronos Group last week was a “smart move” for Altria.

The Horizons Marijuana Life Sciences ETF (HMMJ) had fallen by about 1.2% as of noon on March 20, while the ETFMG Alternative Harvest ETF (MJ) had declined by nearly 0.8%.

Markets rebounded today after the recent sell-off fueled by US-China trade tensions.

On February 18, Canopy Growth (WEED) received a price target upgrade from Canaccord Genuity.

In the second half of 2018, the cannabis industry remained busy. As the cannabis sector experienced a boom, there was a lot of excitement among investors.

The Day reported that New York, New Jersey, Connecticut, and Pennsylvania’s governors met and agreed on basic guidelines for legalizing marijuana.

Cannabis is a hot sector that’s constantly evolving. Right now, how to buy cannabis stocks is a question that’s likely on many investors’ minds.

Cormark Securities raised its target price for Canopy Growth to 40 Canadian dollars from 33 Canadian dollars, which represents an increase of almost 21%.

On December 14, Tilray (TLRY) announced that it’s investing in ROSE LifeScience—a cannabis producer in Quebec.

CIBC downgraded HEXO to “neutral” from “outperform” and reduced the target price to 8.5 Canadian dollars from 9.5 Canadian dollars.

This week is important for the cannabis sector, as Canopy Growth and Aurora Cannabis are both set to report their earnings results on November 14.

Cannabis legalization is a vital topic in the US. Meanwhile, vaping related deaths continue to rise. Will vaping concerns kill the US cannabis dream?

AGLC will allow retail stores in Alberta to sell marijuana vape products. Consumers will likely be able to purchase cannabis vape products in the next two weeks.

Aurora Cannabis should report its fourth-quarter earnings results on Thursday. So far, September has been positive. As of Monday, the stock has gained 8.7%.

Jeffrey Gundlach predicted bitcoin’s (BTC) crash after the cryptocurrency’s peak in December 2017.

Many people expected the Cannabis 2.0 products, including cannabis edibles, to hit the markets by mid-December 2019. However, the products got delayed.

Marijuana is an old but growing market in California. Notably, California became the first state to legalize medical marijuana in 1996.

After Tilray’s second-quarter earnings, Benchmark reduced its target price to $80 from $120. Cowen and Company reduced the target price to $60 from $150.

On May 28, Bill C-45, Canada’s recreational cannabis legalization bill, saw further progress in the Senate.

Canopy Growth (WEED) (CGC) has continued to deepen its roots in the United States with a recent announcement that could be a game changer.

MedMen’s (MMNFF) reported revenues are generated from direct sales through its retail stores. The company has reported no material revenues from cultivation or production wholesale operations.

Last week, the overall cannabis sector remained subdued. Sector ETFs, such as the Horizons Marijuana Life Sciences ETF (HMMJ), closed about 8.15% lower.

Federally, cannabis legalization saw daylight in Canada in 2018. The Cannabis Act legalized recreational marijuana in October 2018. Now, the country is all set for the second wave of legalization, Cannabis 2.0, which includes cannabis edibles, cannabis-infused beverages, extracts, and various other products. Let’s dig into this more. Canada’s second wave of legalization Next month, […]

Deloitte estimates that the newly legalized cannabis beverage market could be worth 529 million Canadian dollars annually in Canada.

After Canada legalized cannabis edibles in October, consumers hoped to buy these products this month. However, three provinces must wait until January.

Cannabis 2.0 legalization will take place in Canada next month. Cannabis players are gearing up to expand in the edibles market.

The reason cannabis stocks are rising could be because October 17 is approaching.

On November 29, Canopy Growth (WEED) entered an 18-month supply agreement with MediPharm Labs.

On January 18, Canopy Growth was trading at an EV-to-EBITDA multiple of 110.9x.

Today, cannabis stocks are trading in the green despite the weakness in the broader market. The ETFMG Alternative Harvest ETF was up 2.5% as of 2:00 PM ET.

Canopy Growth reported its earnings for the first quarter of 2019 on August 14. The company is one of the largest cannabis producers by capacity.

It looks like cannabis stocks had a great day. Innovative Industrial Properties (IIPR), Cronos Group (CRON), and Tilray (TLRY) are all surging today.

On December 9, Canopy Growth (CGC) appointed David Klein as its new CEO effective January 14. He’s the current CFO of Constellation Brands.

Amid a subdued cannabis sector, Aurora Cannabis (ACB) stock has taken a serious hit and is down 36.4% this month. Is this the right time to invest?

During 3Q18, Canopy Growth increased its inventory and biological assets to a value of 108.3 Canadian dollars from 56 million Canadian dollars in 3Q17.

While Aphria’s consensus target price fell after its earnings, most analysts remain bullish on the stock. The overall “strong-buy” rating didn’t change.

Aurora Cannabis reported its fourth-quarter results on Wednesday after the market closed. Did the company impress investors?

Canopy Growth is preparing for the US market, but Tilray (TLRY) is not far behind.

Marijuana products are top-rated among Americans. Illinois will see recreational marijuana products for sale on January 1.

Cannabis stocks had a difficult 2019. Besides cannabis companies losing out on revenue and profitability, many external factors also affected the sector. While pessimism drove the industry this year, a Raymond James analyst predicts things can turn around in 2020. Let’s take a look. Raymond James feels the cannabis sector could rebound On December 16, […]

This morning turned brutal for the overall market with the S&P 500 Index sinking as much as 2.34% through the first half of the day on the back of the trade dispute between the United States and China.

On September 18, cannabis stock Tilray (TLRY) popped about 27% to an all-time high of $153.8 in the mid-day session.

Aurora Cannabis stock got a boost at the beginning of the month. The company updated its guidance for the fourth quarter.

Cannabis ETFs traded on a largely negative note last week.

Aurora Cannabis (ACB) is going through a rough patch. This year, the company’s stock has lost 60.9% of its value as of December 23.

The FDA has issued warning letters to 15 companies involved in illegal sales of non-psychoactive CBD products. What’s the legal market’s potential?

The week ending February 16 wasn’t so positive for marijuana stocks even though the broader market indexes ended in the positive territory.

Cannabis players are having a hard time this year. Regulatory concerns and weaker earnings due to the vaping-related crisis took a toll on the sector.

With more countries now warming up to cannabis, let’s look at how Mexico is shaping up in terms of cannabis legalization.

MedMen released its results for the third quarter of fiscal 2020 on May 27. The stock declined 4.0% and closed at $0.35 on the OTC markets.

The cannabis industry has manufacturing operations in China. The coronavirus outbreak revealed some of the pitfalls in the marijuana supply chain. 

Cannabis is slowly picking up steam again, with more states are pushing to legalize. However, it appears the challenges never end in the marijuana sector.

Today, Planet 13 Holdings (PNTH) (PLNHF) announced that it had inked a purchase agreement with Tyson Ranch, which is owned by boxer Mike Tyson.

The cannabis sector has seen a bit of a Jekyll and Hyde situation in 2019. In the first half, cannabis ETFs rose, but in the second half, they plummeted.

Cannabis legalization is gaining traction not only in the US but also globally. The third presidential Democratic debate was held on September 12.

Today, Aurora Cannabis (ACB)(ACBFF) announced that it agreed to acquire all of MedReleaf’s (MEDFF) outstanding common shares for about 3.2 billion Canadian dollars.

On July 10, Canopy Growth (WEED) (CGC) announced that it had entered an agreement to acquire Hiku Brands Company (HIKU).

The spotlight is on marijuana legalization as the demand keeps surging. More states have stepped up to legalize either recreational or medical cannabis.

So far, cannabis stocks have rebounded in 2020, which investors expected. The marijuana industry struggled in 2019. Overall, the rebound will take time.

Cronos Group and Aphria are Jim Cramer’s top picks in the cannabis sector. Aphria’s upbeat earnings results restored investors’ faith in the sector.

Cannabis legalization has taken a back seat in the US. Since the last Democratic debate, there hasn’t been much discussion about federal legalization.

On Friday, Canopy Growth will report its third-quarter earnings before the market opens. Investors will be watching the results closely.

Since Peltz has experience in the consumer market space, Aurora Cannabis is probably looking to make a deeper foray into the consumer space.

Marijuana stocks are seeing a ray of hope amid the coronavirus pandemic. With self-quarantine and lockdowns in many cities, marijuana sales have risen.

Investors and analysts weren’t pleased with Acreage Holdings’ (OTCMKTS:ACRGF) results for the first quarter of 2020. The company posted another EBITDA loss.

Earlier this week, Rahul Sarugaser of Raymond James upgraded Cronos Group (NASDAQ:CRON) from “market perform” to “outperform.”

Aurora Cannabis (NYSE:ACB) announced some business transformation plans on June 23. The plans included cost savings and margin improvement.

On Tuesday, Aurora Cannabis (NYSE:ACB) provided an update on its business transformation plan, which it announced earlier this year.

In April, cannabis sales came in at $180.1 million—0.6% down from the March sales. So, considering the spike in March, the sales weren’t disappointing.

On Wednesday, HEXO announced a new at-the-market equity program, which would allow it to issue common shares worth up to 34.5 million Canadian dollars.

On June 11, Charlotte’s Web announced that it completed the acquisition of Abacus Health. The company’s performance wasn’t strong in the first quarter.

On Wednesday, OrganiGram Holdings (NASDAQ:OGI) announced that its subsidiary OrganiGram signed a supply agreement with Canndoc.

On Monday, Green Thumb Industries (OTCMKTS:GTBIF) opened a Rise brand store in Chambersburg, Pennsylvania—its 46th store in the US.

Since Canopy Growth (NYSE:CGC)(TSE:WEED) reported its results for the fourth quarter of fiscal 2020, it has lost 22.4% of its stock value as of Tuesday.

HEXO (TSE:HEXO) will likely report its third-quarter earnings before the market opens on June 11. So far, HEXO has lost 58.9% of its stock value this year.

As of June 5, Aurora Cannabis was trading at 18.79 Canadian dollars—a rise of 104.2% since it reported its third-quarter earnings.

Layoffs amid COVID-19 led to a decline in disposable income, which had a negative impact on the cigarette and cannabis industries.

Paradigm Capital analyst Corey Hammill is bullish on OrganiGram. He rated the stock as a “buy” with a target price of 4.00 Canadian dollars.

On Wednesday, HEXO launched its high-THC strain Tsunami in a new 30-gram pack exclusively for medical usage. The launch impressed investors.

Canopy Growth (NYSE:CGC)(TSE:WEED) reported its fourth-quarter earnings before the market opened on May 29. The company’s earnings were weak.

On Monday, HEXO announced that it received a license amendment from Health Canada for its manufacturing and processing facility in Belleville, Ontario.

Canadian cannabis companies are frustrated by the Jamaican government’s inaction. They have decided to cut their losses and exit the Jamaican market.

Rahul Sarugaser of Raymond James is upbeat on OrganiGram Holdings (NASDAQ:OGI). The company amended its credit facility with the Bank of Montreal.

Since Aurora Cannabis reported its third-quarter earnings, Piper Sandler upgraded the stock from “underweight” to “neutral.” Analysts favor a “hold” rating.

On April 14, Aphria (NYSE:APHA) reported its third-quarter earnings. For the quarter, the company reported revenues of 144.4 million Canadian dollars.

Canopy Growth and Aurora Cannabis are two prominent players in the cannabis sector. So far in 2020, Canopy Growth has outperformed cannabis ETFs.

Analysts expect Aphria to report revenue of 130.6 million Canadian dollars in the third quarter—growth of 77.5% YoY and a sequential increase of 8.3%.

On April 6, Bruce Linton said that Canopy Growth (TSE:WEED) and Cronos Group (NASDAQ:CRON) are better equipped to withstand the COVID-19 storm.

As of April 3, Aurora Cannabis stock has fallen 10%, while Canopy Growth has fallen 8.1%. Cronos Group and Hexo have fallen 2.6% and 19.3% in April.

So far this year, OrganiGram Holdings (NASDAQ:OGI) and Aphria (NYSE:APHA) have lost 11.0% and 36.7% of their stock price.

As the markets start to rebound, three cannabis stocks could deliver strong returns. Cannabis sales have increased amid the coronavirus outbreak.

Currently, the cannabis industry has pleaded with the federal government to help cannabis businesses during these distressing times.

Last week was the worst week since October 2008. However, the cannabis sector fared better than the broader equity markets.

On March 19, Bank of America upgraded Aphria (NYSE:APHA) and OrganiGram Holdings (NASDAQ:OGI) due to the increased demand for cannabis.

Curaleaf Holdings (OTCMKTS:CURLF) will report its fourth-quarter earnings after the market closes on March 24. Analysts are bullish on Curaleaf.

Charlotte’s Web Holdings (NYSEARCA:CWEB) will report its earnings for the fourth quarter of 2019 before the market opens on March 24.

On March 16, Roth Capital initiated coverage on Innovative Industrial Properties (NYSE:IIPR) with a “buy” rating and a stock price of $110.

The marijuana sector saw a sharp decline last week amid the global sell-off. The S&P 500 fell by 8.8% in the week ending on March 13.

As of Thursday, nine analysts covered Curaleaf. Among the analysts, eight recommend a “buy,” while one recommends a “hold.”